BeStock  
Markets › Compare › ABUS vs NVCT

ABUS vs NVCT

Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.

vsvs
ABUS · Arbutus Biopharma$4.02 ▼ 1.23%
NVCT · Nuvectis Pharma$19.39 ▼ 2.27%

One year, rebased to 100

Each line starts at 100 so growth is directly comparable

62172281390500Nov 24, '25May 26, '26Nov 20, '26
  • ABUS -5.9%
  • NVCT +223.7%

Head to head

MetricABUSNVCT
Price$4.02$19.39
Change today▼ 1.23%▼ 2.27%
Market cap$616.24M$666.80M
Return, 3 months-22.7%-18.8%
Return, year to date-16.4%+156.8%
Return, 1 year-6.7%+218.9%
P/E (TTM)3.6–
P/B7.25.3
P/E percentile vs own 5y90th22nd
Dividend yield––
Revenue growth (YoY, latest qtr)-43.5%–
Net profit growth (YoY)+863.6%-303.0%
Gross margin––
Operating margin80.1%–
Net margin121.2%–
Return on equity269.6%-67.0%
Analyst target vs. price–+77.9%
Analyst buy share–100%
RSI (14)4647
30-day volatility45.2%78.4%
Max drawdown, 1 year-29.9%-37.7%
Trend readStrong downtrendLeaning bearish
Analyst consensus–Buy

Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.

What the numbers say

  • NVCT is the largest of the group by market value.
  • NVCT has returned the most over the past year.
  • ABUS has been the calmest stock over the last 30 days.

Go deeper

Scroll to Top